Insomnia and depression often go hand-in-hand. Although just 15 percent of people with depression sleep too much, as many as 80 percent have trouble falling asleep or staying asleep. There are treatments available for anxiety, depression and insomnia, but many antidepressant drugs have serious side-effects. Cervella Cranial Electrotherapy Stimulator (CES) is a non-drug alternative for treating anxiety, depression and insomnia. Cervella can be also used in conjunction with drug or cognitive therapies making it an excellent adjunct device.
“Anxiety, insomnia, and depression are disorders affecting at least 20% of adult population. Furthermore, recent research brought to light that 70% of teenagers list anxiety and depression as the main problem affecting the younger population. For many years, CES devices have been clinically validated as a safe and effective alternative to drug-based therapies without the side-effects that often exist with the use of antidepressants,” said Mr. Bart Waclawik, President and CEO of Innovative Neurological Devices.
The FDA-cleared device works by delivering micro pulses of electrical current across a patient’s brain. According to clinical studies, this electrical stimulation results in reduction in anxiety levels, insomnia, and patient’s depressive mood, says a press release.
The proprietary conductive treatment electrodes have been seamlessly integrated into noise-cancelling Bluetooth-enabled headphones. Patients can use the audio and noise cancelling features of the headphones during treatment, which allows them to use the device during study, work, or play. Furthermore, Cervella is also the first CES device that is managed through an app on a smart device allowing for automated treatment data recording, reminders, and analytics aimed at improving patient treatment outcomes. In sum, Cervella is designed to fit into a patient’s lifestyle, not the other way around.
“The current situation, resulting from the pandemic and exacerbated by the recent socio-political unrest, has really increased the prevalence of anxiety, depression, and insomnia among the American population,” said Mr. Waclawik.